Full Press Release Details
Announces Strategic Co-Development Partnership with Lantheus for Australia
Sydney, Australia - 30 December 2024 - Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"),
a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical
need, is pleased to announce that it has entered into a strategic co-development partnership with Lantheus to advance the clinical development
of innovative radiopharmaceuticals in Australia.
Under the agreement, Radiopharm will lead clinical development efforts
in Australia, leveraging its extensive experience and infrastructure to drive advancements in the field. The collaboration includes plans
for a basket clinical trial targeting multiple solid tumors, underscoring both companies' commitment to addressing unmet medical needs
As part of the partnership, Lantheus will cover all clinical development
costs associated with the program. Additionally, Radiopharm will receive up to USD 2 million as milestone payments upon achieving key
clinical development objectives, including ethics committee approval, first patient dosing, and completion of patient enrolment, for the
first imaging trial subject to this agreement.
Lantheus CEO Brian Markison commented, "This partnership is an
important step forward in our purpose to advance our best-in-class radiopharmaceutical therapies. Radiopharm's deep expertise and
capabilities in Australia make them an ideal collaborator for this endeavor."
Riccardo Canevari, CEO of Radiopharm, stated, "We are thrilled
to collaborate with Lantheus, a global leader in radiopharmaceuticals. This partnership strengthens our ability to bring innovative treatments
to patients in need and demonstrates the power of combining our expertise and resources."
About Radiopharm Theranostics
Radiopharm Theranostics is a clinical stage radiotherapeutics company
developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high
unmet medical need. Radiopharm has been listed on ASX (RAD) since November 2021. The company has a pipeline of six distinct and highly
differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and
clinical stages of development from some of the world's leading universities and institutes. The pipeline has been built based on
the potential to be first-to-market or best-in-class. The clinical program includes one Phase II and two Phase I trials in a variety of
solid tumour cancers including lung, pancreas, and brain. Learn more at radiopharmtheranostics.com.
Radiopharm Theranostics
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
Authorized on behalf of the Radiopharm Theranostics Board of Directors
by Executive Chairman Paul Hopper.
For more information:
CEO & Managing Director
Follow Radiopharm Theranostics:
Website - https://radiopharmtheranostics.com/
Twitter - https://twitter.com/TeamRadiopharm
InvestorHub - https://investorhub.radiopharmtheranostics.com/
Radiopharm Theranostics
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia